Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Circle collaborates with payment infrastructure Pockyt to support USDC merchant transactions

Circle collaborates with payment infrastructure Pockyt to support USDC merchant transactions

Bitget2024/12/05 14:49

According to official news, Circle has announced a partnership with payment infrastructure Pockyt to support USDC merchant transactions. This collaboration will redefine the possibilities for businesses by incorporating stablecoin payment processing into Pockyt's ecosystem, providing merchants with a secure, efficient and cost-effective solution for cross-border business using USDC. In addition to integrating USDC, Pockyt will also utilize Circle's programmable wallet to connect traditional Web2 financial systems with Web3's decentralized features, enabling thousands of merchants and over one million Pockyt users to seamlessly transition between Web2 and Web3.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5.7 billion patent verdict has been issued, Burford Capital (BUR.US) may receive $1.4 billion, and its share price soared by more than 12%.

Burford Capital Ltd. surged more than 12% on Monday, marking its largest intraday increase since the end of March, after a federal jury delivered a verdict in a patent case involving Apple.

智通财经•2026/09/29 03:11

Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) seek dismissal of Bayer’s Monsanto mRNA patent lawsuit, but the judge rejects the request

A federal judge in Delaware on Monday rejected the requests from Pfizer, BioNTech, and Moderna to dismiss a lawsuit filed against them by Monsanto, a subsidiary of the German pharmaceutical giant Bayer. The lawsuit concerns these pharmaceutical companies' use of a patent related to mRNA technology.

智通财经•2026/09/29 02:46